Evidence map›Paper›PMID 32201951›Full record

ReviewEpilepsia2020

Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs.

Solène Thieffry, Pavel Klein, Michel Baulac, Jonathan Plumb, Barbara Pelgrims, Sara Steeves, Simon Borghs

Open access · hybridAbstract readReview
In one paragraph

Review in Epilepsia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Solène ThieffryUCB Pharma, Brussels, Belgium.ORCID 0000-0003-2286-3299
Pavel KleinMid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland.ORCID 0000-0001-7244-3722
Michel BaulacDepartment of Neurology, Pitié-Salpêtrière Hospital & ICM (Brain & Spine Institute), Sorbonne University, Paris, France.
Jonathan PlumbUCB Pharma, Brussels, Belgium.
Barbara PelgrimsUCB Pharma, Brussels, Belgium.
Sara SteevesCostello Medical, Cambridge, UK.ORCID 0000-0002-1192-4810
Simon BorghsUCB Pharma, Slough, UK.ORCID 0000-0003-1081-7981
UCB Pharma (Belgium) · BECostello Medical Consulting (United Kingdom) · GBGeorge Washington University · USSorbonne Université · FRUCB Pharma (United Kingdom) · GB

Funding

UCB Pharma
6 · The paper itself

Abstract

objectiveHead-to-head randomized controlled trials (RCTs) are the gold standard for assessing comparative treatment effects. In the absence of direct comparisons between all possible antiepileptic drugs (AEDs), however, clinical decision-making in focal (partial onset) epilepsy relies on alternative evidence borne from indirect comparisons including network meta-analyses (NMAs) and from real-world evidence (RWE) studies. We review NMAs and observational RWE studies comparing AEDs in the adjunctive setting to compare the robustness of these methods and to formulate recommendations for future evidence development.

methodsA literature review identified NMAs and RWE studies comparing AEDs for the adjunctive treatment of focal seizures published between January 2008 and October 2018. NMAs were evaluated for robustness using a framework based on guidelines from the National Institute for Health and Care Excellence Decision Support Unit and the International Society for Pharmacoeconomics and Outcomes Research. RWE studies were evaluated using the GRACE checklist.

resultsFrom a total of 1993 records, 11 NMAs and six RWE studies were eligible. Key limitations identified in the NMAs include nonsystematic selection of RCTs, unexplored heterogeneity between included RCTs in terms of study and patient characteristics, and selection of AEDs and AED doses or dosing strategies that are not reflective of clinical practice. The main limitations of RWE studies concern sample size, design, and analysis methods. Approximately 90% of comparisons between individual AEDs were nonsignificant in the NMAs. None of the RWE studies adjusted for baseline differences between comparator groups; therefore, they lack the validity to make comparative conclusions. SIGNIFICANCE: Current NMAs and RWE studies provide only nominal comparative evidence for AED treatments in focal epilepsy, and should be used with caution for decision-making due to their methodological limitations. To overcome these hurdles, adherence to methodological guidelines and concerted efforts to collect relevant outcome data in the real world are needed.

Indexed as

Comparative Effectiveness ResearchNetwork Meta-Analysis as TopicObservational Studies as TopicAnticonvulsantsEpilepsies, PartialHumansAnticonvulsantsadjunctivepartial onsetrandomized controlled trialRWEseizure

Identifiers

PMID32201951
PMCPMC7216985
OpenAlexW3012636246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.